Ardelyx (ARDX) News Today → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free ARDX Stock Alerts $6.90 +0.15 (+2.22%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 26 at 3:42 AM | americanbankingnews.comArdelyx (NASDAQ:ARDX) Stock Rating Reaffirmed by Piper SandlerMay 26 at 2:46 AM | americanbankingnews.comArdelyx (NASDAQ:ARDX) Shares Down 3.6% May 26 at 2:12 AM | americanbankingnews.comArdelyx, Inc. (NASDAQ:ARDX) Receives Consensus Rating of "Buy" from BrokeragesMay 26 at 2:10 AM | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Receives Average Rating of "Buy" from AnalystsShares of Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) have been assigned a consensus rating of "Buy" from the nine research firms that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has issued aMay 25 at 9:47 AM | americanbankingnews.comWedbush Reaffirms Outperform Rating for Ardelyx (NASDAQ:ARDX)May 24, 2024 | msn.comArdelyx slips as commercial chief departsMay 24, 2024 | marketbeat.comArdelyx's (ARDX) "Overweight" Rating Reaffirmed at Piper SandlerPiper Sandler reiterated an "overweight" rating and issued a $15.00 target price on shares of Ardelyx in a research note on Friday.May 24, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Trading Down 3.6%Ardelyx (NASDAQ:ARDX) Trading Down 3.6%May 22, 2024 | benzinga.comLatest News for Ardelyx Stock (NASDAQ:ARDX)May 22, 2024 | globenewswire.comArdelyx to Participate at the 2024 Jefferies Global Healthcare ConferenceMay 22, 2024 | marketbeat.comBNP Paribas Financial Markets Acquires 393,801 Shares of Ardelyx, Inc. (NASDAQ:ARDX)BNP Paribas Financial Markets grew its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 156.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 644,975 shares of the biopharmaceutical company's stockMay 22, 2024 | americanbankingnews.comArdelyx (NASDAQ:ARDX) versus Galapagos (NASDAQ:GLPG) Head-To-Head ReviewMay 21, 2024 | globenewswire.comArdelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in AdultsMay 21, 2024 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Lowered to "Sell" at StockNews.comMay 19, 2024 | investorplace.comThe 3 Best Penny Stocks to Buy in May 2024May 17, 2024 | marketbeat.comRussell Investments Group Ltd. Acquires 267,183 Shares of Ardelyx, Inc. (NASDAQ:ARDX)Russell Investments Group Ltd. grew its stake in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 392,916.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 267,251 shares of the biopharmaceuticMay 16, 2024 | insidertrades.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 3,000 Shares of StockMay 16, 2024 | globenewswire.comArdelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)May 15, 2024 | msn.comArdelyx (NASDAQ:ARDX): A Commercial-Stage Biopharma Stock with Growth PotentialMay 14, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Shares Down 3.7% Ardelyx (NASDAQ:ARDX) Trading Down 3.7%May 14, 2024 | globenewswire.comArdelyx, Inc. Reports Employment Inducement GrantsMay 10, 2024 | seekingalpha.comArdelyx: Strong Execution, Fairly ValuedMay 10, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) Insider Sells $1,832,374.28 in StockMay 9, 2024 | marketbeat.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) Insider Sells 207,988 Shares of StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Robert Ora Felsch sold 207,988 shares of Ardelyx stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $8.81, for a total transaction of $1,832,374.28. Following the transaction, the insider now owns 95,947 shares of the company's stock, valued at approximately $845,293.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.May 8, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Stock Price Down 8.1% on Insider SellingArdelyx (NASDAQ:ARDX) Shares Down 8.1% Following Insider SellingMay 8, 2024 | insidertrades.comLaura A. Williams Sells 39,949 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockMay 7, 2024 | globenewswire.comArdelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week ConferenceMay 4, 2024 | finance.yahoo.comArdelyx First Quarter 2024 Earnings: Beats ExpectationsMay 4, 2024 | finance.yahoo.comArdelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Announces Quarterly Earnings ResultsArdelyx (NASDAQ:ARDX - Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The company had revenue of $46.00 million during the quarter, compared to the consensus estimate of $36.40 million. Ardelyx had a negative net margin of 53.08% and a negative return on equity of 43.57%. The firm's revenue was up 303.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.13) earnings per share.May 3, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Shares Gap Up Following Strong EarningsArdelyx (NASDAQ:ARDX) Shares Gap Up Following Strong EarningsMay 3, 2024 | marketbeat.comStock Traders Buy High Volume of Call Options on Ardelyx (NASDAQ:ARDX)Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) saw unusually large options trading on Friday. Stock investors acquired 18,613 call options on the company. This is an increase of approximately 219% compared to the typical daily volume of 5,838 call options.May 3, 2024 | seekingalpha.comArdelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)May 3, 2024 | marketwatch.comArdelyx Shares Rally Premarket as 1Q Revenue Tops Street ViewsMay 2, 2024 | investorplace.comARDX Stock Earnings: Ardelyx Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | sfgate.comArdelyx: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comArdelyx Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | insidertrades.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 30,000 Shares of StockMay 1, 2024 | globenewswire.comArdelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical MeetingsApril 30, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Trading Up 4%Ardelyx (NASDAQ:ARDX) Trading 4% HigherApril 28, 2024 | marketbeat.comabrdn plc Takes Position in Ardelyx, Inc. (NASDAQ:ARDX)abrdn plc purchased a new stake in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 833,614 shares of the biopharmaceutical company's stock, valued at approximately $5April 23, 2024 | finance.yahoo.comArdelyx's (NASDAQ:ARDX) investors will be pleased with their favorable 91% return over the last five yearsApril 19, 2024 | marketbeat.comAnalysts Issue Forecasts for Ardelyx, Inc.'s Q1 2024 Earnings (NASDAQ:ARDX)Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Stock analysts at Wedbush lowered their Q1 2024 earnings per share estimates for Ardelyx in a research note issued to investors on Wednesday, April 17th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings of ($0April 18, 2024 | investing.comArdelyx CEO Michael Raab sells $52,923 in company stockApril 18, 2024 | finance.yahoo.comArdelyx to Report First Quarter 2024 Financial Results on May 2, 2024April 18, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 7,500 SharesApril 17, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Given New $14.00 Price Target at WedbushWedbush boosted their price target on shares of Ardelyx from $13.00 to $14.00 and gave the company an "outperform" rating in a report on Wednesday.April 16, 2024 | finance.yahoo.comArdelyx, Inc. (ARDX) Interactive Stock Chart - Yahoo FinanceApril 9, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Given "Outperform" Rating at Leerink PartnrsLeerink Partnrs restated an "outperform" rating on shares of Ardelyx in a research report on Friday.April 8, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Trading Down 2.9%Ardelyx (NASDAQ:ARDX) Shares Down 2.9% Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street Legend Warns: "A Strange Day Is Coming to America" (Ad)Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more. ARDX Media Mentions By Week ARDX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARDX News Sentiment▼0.490.92▲Average Medical News Sentiment ARDX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARDX Articles This Week▼175▲ARDX Articles Average Week Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EVO News Today PTGX News Today AGIO News Today KROS News Today NAMS News Today GLPG News Today SNDX News Today KURA News Today CPRX News Today HRMY News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARDX) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestWARNING about the death of the U.S. dollar…Colonial MetalsThe only AI company to buyPorter & CompanyBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist My Default Watchlist Adding Ardelyx, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
